首頁 > 市場調查報告書 > 醫療設備

體外診斷生技設備

市場調查報告書

商品編碼

1562483

組織診斷市場規模、佔有率、成長分析、按產品類型、按技術、按疾病類型、按最終用戶、按地區 - 行業預測，2024-2031 年

Tissue Diagnostics Market Size, Share, Growth Analysis, By Product, By Technology, By Disease Type, By End User, By Region - Industry Forecast 2024-2031

出版日期: 2024年09月09日 | 出版商:

SkyQuest | 英文 242 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2022年全球組織診斷市場規模為51.7億美元，從2023年的56億美元成長到2031年的106.8億美元，複合年成長率預計為8.4%。

由於慢性病，尤其是癌症的盛行率不斷增加，全球組織診斷市場正在穩步成長。組織診斷是識別細胞層面異常的重要過程，對於準確診斷癌症和其他疾病至關重要。由於人們越來越意識到早期診斷的好處，對疾病早期檢測的需求不斷成長，正在推動市場擴張。主要企業正在專注於自動化和數位病理學等技術進步，以提高診斷的準確性和速度。此外，醫療保健支出的增加、研發投資以及先進診斷技術的整合正在進一步推動市場成長。包括試劑和抗體在內的消耗品仍然是主要產品領域，因為它們在診斷過程中被重複使用。隨著精準醫療和個人化治療的廣泛採用以及對先進診斷工具的需求，預計該市場將繼續成長。

市場概況
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲 (MEA)
- 海灣合作理事會國家
- 南非
- 其他中東/非洲地區

競爭格局

前5名企業對比
主要企業市場定位（2023年）
主要市場參與者所採取的策略
近期市集活動
主要企業市場佔有率（2023年）

主要企業簡介

F. Hoffmann-La Roche Ltd.（Switzerland）
Danaher Corporation（US）
PHC Holdings Corporation（Japan）
Thermo Fisher Scientific Inc.（US）
Abbott（US）
Agilent Technologies, Inc.（US）
Merck KGaA（Germany）
Sakura Finetek Japan Co., Ltd.（Japan）
Abcam Plc（UK）
Becton, Dickinson and Company（US）
Bio SB（US）
BioGenex（US）
Cell Signaling Technology, Inc.（US）
Histo-Line Laboratories（Italy）
Slee Medical GmbH（Germany）
CellPath Ltd.（UK）
Amos Scientific Pty Ltd.（Australia）
Jinhua Yidi Medical Appliance Co., Ltd.（China）
Medite Medical GmbH（Germany）
Diapath SpA（Italy）

簡介目錄

Product Code: SQMIG35H2161

Global Tissue Diagnostics Market size was valued at USD 5.17 billion in 2022 and is poised to grow from USD 5.60 billion in 2023 to USD 10.68 billion by 2031, growing at a CAGR of 8.4% in the forecast period (2024-2031).

Global tissue diagnostics market is experiencing robust growth due to the increasing prevalence of chronic diseases, particularly cancer. Tissue diagnostics is a critical process in identifying abnormalities at the cellular level, which is essential for diagnosing cancers and other conditions accurately. The rising demand for early detection of diseases, driven by a growing awareness of the benefits of early diagnosis, is propelling market expansion. Key players are focusing on technological advancements, such as automation and digital pathology, to improve diagnostic accuracy and speed. In addition, increasing healthcare expenditure, investments in research and development, and the integration of advanced diagnostic technologies are further driving market growth. Consumables, including reagents and antibodies, remain a dominant product segment due to their recurring usage in diagnostic procedures. The market is poised for continued growth as precision medicine and personalized treatments become more widely adopted, necessitating advanced diagnostic tools.

Top-down and bottom-up approaches were used to estimate and validate the size of the Tissue Diagnostics Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Tissue Diagnostics Market Segmental Analysis

Global Tissue Diagnostics Market is segmented on the basis of product, technology, disease type, end user, and region. By product, market is segmented into consumables, and instruments. By technology, market is segmented into immunohistochemistry, in situ hybridization, digital pathology & workflow management, and special staining. By disease type, market is segmented into breast cancer, gastric cancer, lymphoma, prostate cancer, non-small cell lung cancer, and other disease types. By end user, market is segmented into hospitals, research laboratories, pharmaceutical companies, contract research organizations, and other end users. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Tissue Diagnostics Market

The growing incidence of cancer is a significant driver in the tissue diagnostics market. As cancer remains one of the leading causes of death globally, the demand for accurate and early diagnostic tools has surged. Tissue diagnostics, through techniques like immunohistochemistry (IHC) and in-situ hybridization (ISH), provides detailed insights into tumor morphology and biomarkers. These techniques help in determining the most effective treatment plans for patients, making tissue diagnostics indispensable in cancer care. As awareness of cancer screening increases, and governments and private institutions push for earlier diagnosis and treatment, the adoption of tissue diagnostic tools is expected to rise significantly. The integration of molecular diagnostics with tissue-based techniques is further enhancing the precision of these tests, supporting their use in cancer diagnosis and treatment planning.

Restraints in the Tissue Diagnostics Market

A major restraint in the tissue diagnostics market is the high cost associated with advanced diagnostic procedures. Techniques like immunohistochemistry (IHC) and next-generation sequencing (NGS) require specialized equipment and consumables, which can be costly for healthcare providers. This financial barrier limits the accessibility of these advanced diagnostic solutions, particularly in low- and middle-income regions. Additionally, the lack of adequate reimbursement policies for tissue diagnostics in certain healthcare systems further complicates the situation, discouraging hospitals and diagnostic centers from adopting the latest technologies. These high costs also pose challenges to patients, making it difficult for them to afford critical diagnostic tests, especially in regions where healthcare infrastructure is underdeveloped.

Market Trends of the Tissue Diagnostics Market

The adoption of digital pathology is a significant trend shaping the future of the tissue diagnostics market. Digital pathology involves scanning and digitizing tissue samples, enabling remote analysis, storage, and sharing among pathologists. This technology improves the efficiency of diagnostics, as it allows pathologists to access and interpret data from anywhere in the world, facilitating faster diagnosis. The integration of artificial intelligence (AI) and machine learning into digital pathology is enhancing diagnostic accuracy and helping to detect minute abnormalities that might be missed by the human eye. AI-powered systems are also aiding in the automation of routine diagnostics, reducing workload and improving the speed of analysis. As the adoption of digital pathology accelerates, it is expected to revolutionize the tissue diagnostics market by making diagnostics more accessible, efficient, and accurate.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Ecosystem of the Market
Top Investment Analysis
Key Success Factor
Degree of Competition
Value Chain Analysis
Supply Chain Analysis
Technology Analysis
Regulatory Landscape
Patent Analysis
Pricing Analysis
Trade Analysis

Tissue Diagnostics Market by Product

Market Overview
Consumables
- Antibodies
- Kits
- Reagents
- Probes
Instruments
- Slide-Staining Systems
- Scanners
- Tissue-Processing Systems
- Other Instruments

Tissue Diagnostics Market by Technology

Market Overview
Immunohistochemistry
In Situ Hybridization
Digital Pathology & Workflow Management
Special Staining

Tissue Diagnostics Market by Disease Type

Market Overview
Breast Cancer
Gastric Cancer
Lymphoma
Prostate Cancer
Non-Small Cell Lung Cancer
Other Disease Types

Tissue Diagnostics Market by End User

Market Overview
Hospitals
Research Laboratories
Pharmaceutical Companies
Contract Research Organizations
Other End Users

Tissue Diagnostics Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

F. Hoffmann-La Roche Ltd. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Danaher Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
PHC Holdings Corporation (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abbott (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Agilent Technologies, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck KGaA (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sakura Finetek Japan Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abcam Plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Becton, Dickinson and Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bio SB (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BioGenex (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cell Signaling Technology, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Histo-Line Laboratories (Italy)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Slee Medical GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
CellPath Ltd. (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amos Scientific Pty Ltd. (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Jinhua Yidi Medical Appliance Co., Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Medite Medical GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Diapath S.p.A. (Italy)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments